Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Completed 19Terminated 7Withdrawn 3Unknown 3

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 3

Conditions

Multiple Myeloma 3Sarcoma 2Breast Neoplasms 2Triple Negative Breast Neoplasms 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Recurrence 1Platinum-Refractory Fallopian Tube Carcinoma 1Ovarian Neoplasms 1Osteosarcoma 1Neuroblastoma 1Neoplasm Metastasis 1Lymphoma 1Liver Neoplasms 1Leukemia, Plasma Cell 1Desmoid Tumors 1Carcinoma, Hepatocellular 1

Interventions

Dexamethasone 45Bortezomib 19Lenalidomide 18Calcium Dobesilate 18Melphalan 16Cyclophosphamide 11pomalidomide 10daratumumab 9elotuzumab 8carfilzomib 8pembrolizumab 6ixazomib 6fludarabine phosphate 6dexamethasone acetate 6fludarabine 5dexamethasone 21-phosphate 5Filgrastim 5venetoclax 4selinexor 4auricularum 4Thalidomide 4Tacrolimus 4Peripheral Blood Stem Cell Transplantation 4Magnetic Resonance Spectroscopy 4liposomal doxorubicin 3Whole-Body Irradiation 3Vorinostat 3Nivolumab 3Mycophenolic Acid 3Leukapheresis 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Withdrawn × Multiple Myeloma × liposomal doxorubicin × Clear all
NCT00706953 2015-04-06

A Study of Bortezomib and Pegylated Liposomal Doxorubicin in Patients With Relapsed Multiple Myeloma Previously Treated With Bortezomib

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Phase 2 Withdrawn
Plasma cell

Multiple Myeloma, Recurrence

NCT00516191 2015-03-04

DMV

University of California, San Francisco

Phase 1/2 Withdrawn
Plasma cell

Multiple Myeloma

NCT01492881 2012-05-11

Study of Vorinostat With Doxil and Bortezomib for Patients With Relapsed/Refractory Multiple Myeloma

UNC Lineberger Comprehensive Cancer Center

Phase 2 Withdrawn
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡